Which has better valuation and earnings, AVTE or SBTX?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is AVTE or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Silverback Therapeutics N/A -29.62% -28.20%

Which has stronger valuation & earnings, ELYM or SBTX?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is ELYM or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Silverback Therapeutics N/A -29.62% -28.20%

Which has better valuation and earnings, NLTX or SBTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is NLTX or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Silverback Therapeutics N/A -29.62% -28.20%

Do analysts rate LWAC or SBTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, LWAC or SBTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LightWave Acquisition N/A N/A N/A N/A N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is LWAC or SBTX more profitable?

LightWave Acquisition's return on equity of 0.00% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LightWave Acquisition N/A N/A N/A Silverback Therapeutics N/A -29.62% -28.20%

Do analysts rate TTRX or SBTX?

Turn Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 3.90%. Given Turn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turn Therapeutics is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Turn Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, TTRX or SBTX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.19 N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is TTRX or SBTX more profitable?

Turn Therapeutics' return on equity of 0.00% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A N/A N/A Silverback Therapeutics N/A -29.62% -28.20%

Silverback Therapeutics (SBTX) Competitors

$5.76 -0.18 (-3.03%)

As of 07/27/2026

Compare

SBTX vs. AVTE, ELYM, NLTX, LWAC, and TTRX

Should you buy Silverback Therapeutics stock or one of its competitors? MarketBeat compares Silverback Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silverback Therapeutics include Aerovate Therapeutics (AVTE), Eliem Therapeutics (ELYM), Neoleukin Therapeutics (NLTX), LightWave Acquisition (LWAC), and Turn Therapeutics (TTRX).

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

In the previous week, Aerovate Therapeutics' average media sentiment score of 0.00 equaled Silverback Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Silverback Therapeutics	Neutral

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Silverback Therapeutics' return on equity of -29.62% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Silverback Therapeutics	N/A	-29.62%	-28.20%

74.9% of Silverback Therapeutics shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Silverback Therapeutics beats Aerovate Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Silverback Therapeutics compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Silverback Therapeutics' return on equity of -29.62% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Eliem Therapeutics' average media sentiment score of 0.00 equaled Silverback Therapeutics'average media sentiment score.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Silverback Therapeutics	Neutral

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Summary

Silverback Therapeutics beats Eliem Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Silverback Therapeutics compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

In the previous week, Neoleukin Therapeutics' average media sentiment score of 0.00 equaled Silverback Therapeutics'average media sentiment score.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Silverback Therapeutics	Neutral

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Silverback Therapeutics' return on equity of -29.62% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Summary

Silverback Therapeutics beats Neoleukin Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Silverback Therapeutics compare to LightWave Acquisition?

LightWave Acquisition (NASDAQ:LWAC) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

LightWave Acquisition's return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Silverback Therapeutics	N/A	-29.62%	-28.20%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

74.9% of Silverback Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, LightWave Acquisition had 3 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for LightWave Acquisition and 0 mentions for Silverback Therapeutics. LightWave Acquisition's average media sentiment score of 1.84 beat Silverback Therapeutics' score of 0.00 indicating that LightWave Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
LightWave Acquisition	Very Positive
Silverback Therapeutics	Neutral

Summary

LightWave Acquisition beats Silverback Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Silverback Therapeutics compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

74.9% of Silverback Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Turn Therapeutics had 5 more articles in the media than Silverback Therapeutics. MarketBeat recorded 5 mentions for Turn Therapeutics and 0 mentions for Silverback Therapeutics. Turn Therapeutics' average media sentiment score of 1.18 beat Silverback Therapeutics' score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Turn Therapeutics	Positive
Silverback Therapeutics	Neutral

Turn Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 3.90%. Given Turn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turn Therapeutics is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Turn Therapeutics' return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Silverback Therapeutics	N/A	-29.62%	-28.20%

Turn Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Summary

Turn Therapeutics beats Silverback Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Silverback Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBTX vs. The Competition

Export

Metric	Silverback Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$207.69M	$945.02M	$7.04B	$12.13B
Dividend Yield	N/A	4.84%	2.67%	9.43%
P/E Ratio	-2.38	1.52	27.30	23.79
Price / Sales	N/A	103.71	510.90	89.25
Price / Cash	N/A	22.05	26.39	46.66
Price / Book	0.78	8.58	10.27	6.10
Net Income	-$89.48M	-$3.26M	$3.60B	$336.45M
7 Day Performance	-10.56%	-0.36%	-1.79%	-2.14%
1 Month Performance	-32.55%	-6.22%	-2.66%	-3.31%
1 Year Performance	-67.77%	26.14%	18.22%	13.49%

Silverback Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBTX Silverback Therapeutics	N/A	$5.76 -3.0%	N/A	-66.8%	$207.69M	N/A	N/A	83	High Trading Volume
AVTE Aerovate Therapeutics	N/A	$19.85 -3.3%	N/A	+142.5%	$575.35M	N/A	N/A	20	High Trading Volume
ELYM Eliem Therapeutics	N/A	$12.58 -4.0%	N/A	+785.5%	$374.28M	N/A	N/A	9	Gap Up
NLTX Neoleukin Therapeutics	N/A	$36.11 -1.6%	N/A	+53.6%	$339.36M	N/A	N/A	90	High Trading Volume
LWAC LightWave Acquisition	N/A	$10.24 +0.1%	N/A	N/A	$307.97M	N/A	N/A	N/A	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBTX) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silverback Therapeutics (SBTX) Competitors

SBTX vs. AVTE, ELYM, NLTX, LWAC, and TTRX

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Summary

How does Silverback Therapeutics compare to Eliem Therapeutics?

Summary

How does Silverback Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Silverback Therapeutics compare to LightWave Acquisition?

Summary

How does Silverback Therapeutics compare to Turn Therapeutics?

Summary

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silverback Therapeutics (SBTX) Competitors

SBTX vs. AVTE, ELYM, NLTX, LWAC, and TTRX

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Does the media refer more to AVTE or SBTX?

Which has better valuation and earnings, AVTE or SBTX?

Which has more volatility & risk, AVTE or SBTX?

Is AVTE or SBTX more profitable?

Do institutionals and insiders believe in AVTE or SBTX?

Summary

How does Silverback Therapeutics compare to Eliem Therapeutics?

Is ELYM or SBTX more profitable?

Which has more risk & volatility, ELYM or SBTX?

Do institutionals & insiders believe in ELYM or SBTX?

Does the media favor ELYM or SBTX?

Which has stronger valuation & earnings, ELYM or SBTX?

Summary

How does Silverback Therapeutics compare to Neoleukin Therapeutics?

Which has more risk & volatility, NLTX or SBTX?

Which has better valuation and earnings, NLTX or SBTX?

Does the media prefer NLTX or SBTX?

Do insiders & institutionals have more ownership in NLTX or SBTX?

Is NLTX or SBTX more profitable?

Summary

How does Silverback Therapeutics compare to LightWave Acquisition?

Is LWAC or SBTX more profitable?

Which has higher earnings and valuation, LWAC or SBTX?

Do insiders and institutionals have more ownership in LWAC or SBTX?

Do analysts rate LWAC or SBTX?

Does the media refer more to LWAC or SBTX?

Summary

How does Silverback Therapeutics compare to Turn Therapeutics?

Do insiders & institutionals have more ownership in TTRX or SBTX?

Does the media favor TTRX or SBTX?

Do analysts rate TTRX or SBTX?

Is TTRX or SBTX more profitable?

Which has preferable earnings & valuation, TTRX or SBTX?

Summary

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools